LIVIA Group acquires Patheon facility in Capua, Italy
It produces enzymes, therapeutic proteins and high-value small molecules for pharma and other industries
German investment company LIVIA Group has agreed to buy a manufacturing facility and its employees in Capua, Italy, from Patheon.
No financial details have been revealed.
The independent microbial fermentation-based manufacturing facility has a fermentor capacity of 1,400m3. It produces enzymes, therapeutic proteins and high-value small molecules for applications in the pharma, food, feed, agrochemical and fine chemical industries. It is both FDA and EMEA (Pharma cGMPs) approved as well as ISO 14001 certified and has customers in more than 60 countries. In addition to its regular production, Capua offers pilot plant capabilities for customised product development, process scale-up and validation.
Patheon's President of Drug Substance Services, Lukas Utiger, said: 'We are very pleased to find a buyer for the Capua facility that is focused on servicing existing customers and adding new ones.
'Selling the Capua site is part of Patheon’s efforts to focus its core business strategy as a leading global provider of outsourced, end-to-end pharmaceutical development and manufacturing services. We elected to sell the operations to LIVIA Group, which is very focused on growing the operations and continuing to provide a positive work environment for employees.'
With funds under management amounting to more than €500m, LIVIA Group is an independent industrial holding company and the investment firm of Prof Dr Peter Löw, concentrating on a diverse spectrum of assets.